Article citationsMore>>

Ouchi, K., Sunakawa, Y., Tsuji, A., Shiozawa, M., Kawai, T., Yasui, H., et al. (2025) Genome-Wide DNA Methylation Status as a Biomarker for Clinical Outcomes of First-Line Treatment in Patients with RAS Wild-Type Metastatic Colorectal Cancer: JACCRO CC-13AR. ESMO Open, 10, Article 105076.
https://doi.org/10.1016/j.esmoop.2025.105076

has been cited by the following article:

• TITLE: Beyond TNM Staging: Clinical Significance of Combined Molecular Biomarkers (TP53, Ki67, RAS, and MSI) in Colorectal Cancer

  AUTHORS: Taiyan Zhu

  KEYWORDS: Colorectal Cancer, Precision Medicine, TP53, KRAS, Microsatellite Instability, Ki67, Risk Stratification

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.5, May 7, 2026

  ABSTRACT: Current colorectal cancer management relies on TNM staging and single-gene testing, often failing to capture biological heterogeneity. This study evaluates the synergistic prognostic value of TP53, Ki67, RAS, and MSI in a 120-patient cohort. We identify a high-risk “Triple Hit” phenotype (MSS/RAS-mut/TP53-mut/High-Ki67) that independently predicts poor overall survival, particularly demonstrating significant risk stratification within early-stage disease. Our proposed Combined Molecular Score offers superior prognostic resolution compared to TNM staging alone. This accessible multi-dimensional atlas provides a robust tool for risk assessment, bridging the gap between molecular biology and routine clinical practice while providing a hypothesis-generating framework for future therapeutic intensification.